Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pafolacianine Injection for Intraoperative Imaging in Gastrointestinal Cancer Peritoneal Carcinomatosis
NCT06511037Phase 1Recruiting
- Sponsor
- University of California, Irvine
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pafolacianine in gastrointestinal cancer and peritoneal carcinomatosis (PC), sponsored by University of California, Irvine. Primary endpoints: Cytoreduction Score at 1 year, Sensitivity-True Positive Rate at 1 year and 4 more. Started Nov 2024; status: recruiting.
02
Drugs
pafolacianine
03
Conditions
gastrointestinal cancerperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT06511037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06511037.